Generative AI to Transform Clinical Development
In an industry where 80% of studies face delays and less than half of clinical trials are completed without full enrolment, AI offers a groundbreaking solution to address these challenges.
*Can't access content? Click here.
Commentary and analysis by leading pharma experts:
- Jonathan Crowther, Head of Predictive Analytics, Pfizer
- Tomas Kvedaravicius, Senior Director, R&D Generative AI Accelerator and Digital Transformation, GSK
- Jan Seidel, Principal Methodology Statistician, Boehringer Ingelheim
- Daniel Swiercz, Associate Director, Site Engagement, Global Program Lead, GSK
- Deiva Ramachandran, Partner at IBM Consulting and Generative AI-Automation Practice Leader
- Julien Willard, Partner and Global Enterprise Strategy Leader for Life Sciences, IBM
Interested in getting involved in Pharma 2025? Don’t hesitate to reach out to our team and learn more about speaking opportunities.
Kind regards,
Download your whitepaper here
With analysis and case studies from senior leaders at Pfizer, GSK and Boehringer Ingelheim.
By submitting this form, you acknowledge the Thomson Reuters group of companies will process your personal information as described in our Privacy Statement
which explains how we collect, use, store, and disclose your personal information, the consequences if you do
not provide this information, and the way in which you
can access and correct your personal information or submit a complaint.
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.